Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Chen‐Hua Liu(National Taiwan University Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Fu-Jen Lee(Fu Jen Catholic University), Chun‐Chao Chang(Taipei Medical University Hospital), Tsai‐Yuan Hsieh(Tri-Service General Hospital), Wei‐Yu Kao(Taipei Medical University Hospital), Jow-Jyh Huang(St. Martin de Porres Hospital), Jyh-Jou Chen(Chi Mei Medical Center), Chi-Wei Tseng(Tzu Chi University), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Chien‐Ching Hung(National Taiwan University), Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Chun‐Jen Liu(National Taiwan University), Pei–Yuan Su(Changhua Christian Hospital), Yi-Jie Huang(Taichung Veterans General Hospital), Gin‐Ho Lo(E-Da Hospital), Hsueh‐Chou Lai(China Medical University), Ke-Jhang Huang(China Medical University), Chi-Yang Chang(I-Shou University), Po-Yueh Chen(Chia-Yi Christian Hospital), Yu‐Lueng Shih(Tri-Service General Hospital), Chi-Yi Chen(Chia-Yi Christian Hospital), Yu-Jen Fang(National Taiwan University Hospital), Pei-Lun Lee(Chi Mei Medical Center), Chia-Sheng Huang, Chung-Hsin Chang(Fu Jen Catholic University), Ming‐Chang Tsai(Chung Shan Medical University Hospital)
Hepatology International
March 6, 2021
Cited by 32


Related Papers